Exploratory Analysis of LDHA and PSMB4 in Extracellular Vesicles and Their Immunohistochemical Expression in Breast Tumors

Introduction: Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor associated with poor prognosis and variable responses to treatment. Despite the limitations of currently available approaches for disease assessment, liquid biopsy and tumor biomarkers have emerged as promising tools for investigating molecular alterations associated with TNBC. In this context, the identification of candidate proteins and their assessment in tumor samples may provide insights into tumor biology and support the development of novel biomarkers for future clinical applications. Aim: The aim of this study was to explore candidate proteins identified by extracellular vesicle (EV) proteomic analysis and subsequently assess their expression in TNBC tumors by immunohistochemistry. Methods: Proteomic analysis of EVs derived from the blood plasma of patients with TNBC in remission and with tumor recurrence was performed as an exploratory approach to identify candidate proteins associated with recurrence. Subsequently, tumor samples from an independent cohort were evaluated by immunohistochemistry to assess the expression of the selected proteins and explore their associations with survival, histological grade, and clinical staging. The data were analyzed using the Kolmogorov–Smirnov test, Student’s t-test, ANOVA with Tukey’s post hoc test, ROC curve analysis, and Pearson and Spearman correlations, with statistical significance set at p ≤ 0.05. Results: Exploratory EV proteomic analysis identified PSMB4 and LDHA as candidate proteins detected in the recurrence group. In the independent tumor cohort, higher PSMB4 histoscore was associated with advanced clinical staging among patients in remission. LDHA expression showed discriminatory potential between TNBC and benign breast tumors, while higher LDHA expression was associated with shorter survival among patients with recurrent disease. These findings support the expression of the candidate proteins in breast tumors but do not establish their value as circulating biomarkers of recurrence. Conclusions: PSMB4 and LDHA were identified as candidate proteins through exploratory EV proteomic analysis and were subsequently assessed for expression in breast tumors by immunohistochemistry. The findings provide evidence of their expression in the tumor compartment and support further investigation of their biological and clinical relevance. However, the present study does not establish PSMB4 or LDHA as validated biomarkers of recurrence, prognosis, or diagnosis. Further studies using larger, independently defined cohorts and direct assessment of these proteins in circulating EVs are required to determine their potential clinical applicability.

Authors

Institutions

Publication Details

Journal
Journal of Personalized Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/jpm16110581
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploratory Analysis of LDHA and PSMB4 in Extracellular Vesicles and Their Immunohistochemical Expression in Breast Tumors

Lucas Romagnolli, Caroline Patini Rezende, Barbara Maria Frigieri, Fabiana Ferreira de Souza et al.
Journal of Personalized Medicine
Extracellular vesicles in disease
article

Exploratory Analysis of LDHA and PSMB4 in Extracellular Vesicles and Their Immunohistochemical Expression in Breast Tumors

Lucas Romagnolli, Caroline Patini Rezende, Barbara Maria Frigieri, Fabiana Ferreira de Souza, Luiz Gustavo de Almeida Chuffa, Adriana Alonso Novais, Débora Aparecida Pires de Campos Zuccari, Guilherme Henrique Tamarindo, Aparecida Perpetuo Fedossi Silveira, Amanda Amadeu
article en

Abstract

Introduction: Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor associated with poor prognosis and variable responses to treatment. Despite the limitations of currently available approaches for disease assessment, liquid biopsy and tumor biomarkers have emerged as promising tools for investigating molecular alterations associated with TNBC. In this context, the identification of candidate proteins and their assessment in tumor samples may provide insights into tumor biology and support the development of novel biomarkers for future clinical applications. Aim: The aim of this study was to explore candidate proteins identified by extracellular vesicle (EV) proteomic analysis and subsequently assess their expression in TNBC tumors by immunohistochemistry. Methods: Proteomic analysis of EVs derived from the blood plasma of patients with TNBC in remission and with tumor recurrence was performed as an exploratory approach to identify candidate proteins associated with recurrence. Subsequently, tumor samples from an independent cohort were evaluated by immunohistochemistry to assess the expression of the selected proteins and explore their associations with survival, histological grade, and clinical staging. The data were analyzed using the Kolmogorov–Smirnov test, Student’s t-test, ANOVA with Tukey’s post hoc test, ROC curve analysis, and Pearson and Spearman correlations, with statistical significance set at p ≤ 0.05. Results: Exploratory EV proteomic analysis identified PSMB4 and LDHA as candidate proteins detected in the recurrence group. In the independent tumor cohort, higher PSMB4 histoscore was associated with advanced clinical staging among patients in remission. LDHA expression showed discriminatory potential between TNBC and benign breast tumors, while higher LDHA expression was associated with shorter survival among patients with recurrent disease. These findings support the expression of the candidate proteins in breast tumors but do not establish their value as circulating biomarkers of recurrence. Conclusions: PSMB4 and LDHA were identified as candidate proteins through exploratory EV proteomic analysis and were subsequently assessed for expression in breast tumors by immunohistochemistry. The findings provide evidence of their expression in the tumor compartment and support further investigation of their biological and clinical relevance. However, the present study does not establish PSMB4 or LDHA as validated biomarkers of recurrence, prognosis, or diagnosis. Further studies using larger, independently defined cohorts and direct assessment of these proteins in circulating EVs are required to determine their potential clinical applicability.

Journal of Personalized MedicineVol. 16(11)
Faculdade de Medicina de São José do Rio Preto (BR), Hospital de Base (BR), Universidade Federal de Mato Grosso (BR), Brazilian Center for Research in Energy and Materials (BR), Brazilian Biosciences National Laboratory (BR), Instituto de Biociências, Letras e Ciências Exatas, câmpus de São José do Rio Preto (BR), Universidade Estadual Paulista (Unesp) (BR)
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon